# OmicaFlow Expected Results & Interpretation Guide

## Research Question
**Primary Hypothesis**: Are there genes that simultaneously experience:
1. Somatic mutations (DNA level)
2. Transcriptional over-expression (RNA level)
3. Promoter hypomethylation (Epigenome level)

**Clinical Validation**: Does this 3-omics signature identify patient subgroups with worse prognosis?

## Expected Outputs by Module

### M02: DNA Analysis (SNV/CNV)
**Expected for LUAD (Lung Adenocarcinoma):**
- Total mutations: 10,000-50,000 (varies by cohort size)
- Driver genes (MAF ≥ 5%): 50-200 genes
- **Known LUAD drivers to validate**: TP53 (50-60%), KRAS (30-40%), EGFR (15-20%), STK11, KEAP1, NF1
- Mutational burden: 5-10 mutations/Mb (typical for LUAD)

**Success Criteria:**
- ✅ TP53, KRAS, EGFR appear in top 10 driver genes
- ✅ Mutational burden distribution matches published TCGA-LUAD studies

### M03: RNA Analysis (DEG)
**Expected for LUAD:**
- Total DEGs (padj ≤ 0.05, |LFC| ≥ 1.5): 2,000-5,000 genes
- Up-regulated: ~50% of DEGs
- Down-regulated: ~50% of DEGs
- **Known LUAD pathways to validate**: Cell cycle, DNA repair, immune response, EGFR signaling

**Success Criteria:**
- ✅ 2,000-5,000 DEGs identified (if fewer, check QC/thresholds)
- ✅ Enriched pathways include known LUAD biology (cell cycle, immune)

### M04: Methylation Analysis (DMP)
**Expected for LUAD:**
- Total DMPs (padj ≤ 0.05): 10,000-50,000 probes (depends on array type: 450K vs EPIC)
- Hypomethylated probes: ~40-60% (cancer often shows global hypomethylation)
- Hypermethylated probes: ~40-60%
- **Known LUAD methylation**: Tumor suppressor promoters often hypermethylated (e.g., CDKN2A, RASSF1A)

**Success Criteria:**
- ✅ 10,000+ DMPs identified
- ✅ Known tumor suppressors show promoter hypermethylation

### M06: Multi-Omics Integration (NEW - Addresses Your Question)
**Expected for LUAD:**
- Genes with mutation + over-expression: 20-50 genes
- Genes with mutation + over-expression + promoter hypomethylation: **5-20 genes** (your target)
- **Biological interpretation**: These are likely oncogenes activated by multiple mechanisms

**Success Criteria:**
- ✅ Identify 5-20 genes with converging 3-omics alterations
- ✅ At least 1-2 known oncogenes in the list (validates method)
- ✅ Novel candidates for further investigation

### M07: Survival Analysis (NEW - Clinical Validation)
**Expected for LUAD:**
- Patients stratified by 3-omics signature: High-risk vs Low-risk groups
- Survival difference: Hazard Ratio (HR) > 1.5, p-value < 0.05 (significant)
- **Clinical relevance**: High-risk group has worse Overall Survival (OS) or Progression-Free Survival (PFS)

**Success Criteria:**
- ✅ Significant survival difference (log-rank p < 0.05)
- ✅ HR > 1.5 (clinically meaningful)
- ✅ Kaplan-Meier curves show clear separation

## Validation Strategy

### Internal Validation (Within TCGA-LUAD)
1. **Cross-validation**: Split cohort 70/30, train on 70%, validate on 30%
2. **Reproducibility**: Run pipeline twice, compare results (should be identical)
3. **Known biomarkers**: Check if TP53, KRAS, EGFR appear in results

### External Validation (Optional, for High-Impact Journals)
1. **UCSC Xena**: Download independent LUAD cohort, apply same pipeline
2. **GEO datasets**: Validate top genes in independent RNA-seq/methylation studies
3. **Literature comparison**: Compare with published TCGA-LUAD multi-omics studies

## Interpretation Guide

### What if results are unexpected?

**Scenario 1: No genes with 3-omics convergence**
- **Possible causes**: Thresholds too strict (adjust padj, LFC, MAF)
- **Action**: Relax thresholds incrementally (e.g., padj 0.05 → 0.1)

**Scenario 2: Too many genes (>50) with 3-omics convergence**
- **Possible causes**: Thresholds too loose, or biological signal is strong
- **Action**: Rank by effect size (LFC, mutation frequency), focus on top 10-20

**Scenario 3: No survival difference**
- **Possible causes**: Signature not prognostic, or cohort too small
- **Action**: Try different survival endpoints (OS vs PFS), or combine with clinical variables (stage, age)

**Scenario 4: Known drivers missing from results**
- **Possible causes**: QC filtering too strict, or data download incomplete
- **Action**: Check QC logs, verify TCGA data completeness

## Publication Strategy

### Target Journals (Based on Results Quality)
1. **High-impact (IF > 10)**: *Nature Communications*, *Genome Medicine*, *Clinical Cancer Research*
   - Requires: Novel genes + strong survival validation + external validation
2. **Mid-impact (IF 5-10)**: *Molecular Cancer*, *Cancers*, *Frontiers in Oncology*
   - Requires: Clear 3-omics integration + survival validation
3. **Methods/Tools (IF 3-5)**: *Bioinformatics*, *BMC Bioinformatics*
   - Focus: Pipeline as a tool, LUAD as proof-of-concept

### Key Figures for Paper
1. **Figure 1**: Pipeline overview (flowchart)
2. **Figure 2**: Individual omics results (volcano plots, heatmaps)
3. **Figure 3**: Multi-omics integration (Venn diagram, heatmap of converging genes)
4. **Figure 4**: Survival analysis (Kaplan-Meier curves, forest plot)
5. **Figure 5**: Validation (external cohort, known biomarkers)

## Resource Estimation (For HPC Planning)

### Estimated Runtime (TCGA-LUAD, ~500 samples)
- M00 Acquisition: 2-4 hours (depends on network speed)
- M01 QC: 30 min - 1 hour
- M02 DNA: 1-2 hours
- M03 RNA: 2-4 hours (DESeq2 is slow for large matrices)
- M04 Methylation: 1-2 hours
- M06 Integration: 30 min
- M07 Survival: 30 min
- **Total: 8-15 hours** (with 32-64 cores)

### Estimated Memory (Peak)
- M03 RNA (DESeq2): 16-32 GB (largest)
- M04 Methylation: 8-16 GB
- Other modules: < 8 GB
- **Recommended: 64 GB RAM** (your HPC spec is sufficient)

### Local Laptop Feasibility
- **Possible but slow**: 8-16 GB RAM, 4-8 cores
- **Recommendation**: Use test dataset first, then subset of TCGA (50-100 samples) on laptop
- **Full cohort (500 samples)**: Better on HPC

## Next Steps
1. Add M06 (Multi-Omics Integration) module to find converging genes
2. Add M07 (Survival Analysis) module to test prognosis
3. Run on test dataset to validate workflow
4. Run on TCGA-LUAD subset (50 samples) to estimate resources
5. Run on full TCGA-LUAD cohort on HPC
6. Validate results against known biomarkers and published studies